Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature

Kristina Khazeni, Hannah LaBove, Breelyn Wilky, Andrew E. Rosenberg, Elizabeth Paulus, Harvey Chim, Joseph M. Pearson, Danny Yakoub

Research output: Contribution to journalArticle

Abstract

Introduction: Myoepithelial carcinoma and proximal-type epithelioid sarcoma of the vulva are two rare malignancies with known aggressive behavior. In addition to a similar clinical course, these two disease entities also have significant histologic and pathologic overlap. Given the rarity of these malignancies, there is limited literature on the appropriate treatment regimen. Nevertheless, there is a consensus that early surgical resection is beneficial in both cases. Presentation: We present a case of a patient who was initially diagnosed with myoepithelial carcinoma of the vulva with a differential later expanded to include possible epithelioid sarcoma. Discussion: We demonstrate the importance in early identification of a SMARCB1 deficiency. Additionally, we suggest an appropriate treatment regimen for these patients going forward. Specifically, we encourage consideration of bilateral superficial and deep inguinal lymphadenectomies. Furthermore, sarcoma based chemotherapy regimens in the appropriate clinical setting may be beneficial in treating SMARCB1 deficient tumors. Additionally, there are now clinical trials involving EZH2 Inhibitors which may offer benefit for similar patients going forward. Conclusion: This case highlights the difficulty in making a definitive diagnosis, and the importance in identifying a SMARCB1 deficiency as it will affect treatment options and may allow for enrollment in ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalInternational Journal of Surgery Case Reports
Volume49
DOIs
StatePublished - Jan 1 2018

Fingerprint

Sarcoma
Vulva
Carcinoma
Clinical Trials
Neoplasms
Groin
Lymph Node Excision
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature. / Khazeni, Kristina; LaBove, Hannah; Wilky, Breelyn; Rosenberg, Andrew E.; Paulus, Elizabeth; Chim, Harvey; Pearson, Joseph M.; Yakoub, Danny.

In: International Journal of Surgery Case Reports, Vol. 49, 01.01.2018, p. 239-243.

Research output: Contribution to journalArticle

Khazeni, Kristina ; LaBove, Hannah ; Wilky, Breelyn ; Rosenberg, Andrew E. ; Paulus, Elizabeth ; Chim, Harvey ; Pearson, Joseph M. ; Yakoub, Danny. / Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature. In: International Journal of Surgery Case Reports. 2018 ; Vol. 49. pp. 239-243.
@article{98b0b5086e994e22a82c6e7e8e32704f,
title = "Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature",
abstract = "Introduction: Myoepithelial carcinoma and proximal-type epithelioid sarcoma of the vulva are two rare malignancies with known aggressive behavior. In addition to a similar clinical course, these two disease entities also have significant histologic and pathologic overlap. Given the rarity of these malignancies, there is limited literature on the appropriate treatment regimen. Nevertheless, there is a consensus that early surgical resection is beneficial in both cases. Presentation: We present a case of a patient who was initially diagnosed with myoepithelial carcinoma of the vulva with a differential later expanded to include possible epithelioid sarcoma. Discussion: We demonstrate the importance in early identification of a SMARCB1 deficiency. Additionally, we suggest an appropriate treatment regimen for these patients going forward. Specifically, we encourage consideration of bilateral superficial and deep inguinal lymphadenectomies. Furthermore, sarcoma based chemotherapy regimens in the appropriate clinical setting may be beneficial in treating SMARCB1 deficient tumors. Additionally, there are now clinical trials involving EZH2 Inhibitors which may offer benefit for similar patients going forward. Conclusion: This case highlights the difficulty in making a definitive diagnosis, and the importance in identifying a SMARCB1 deficiency as it will affect treatment options and may allow for enrollment in ongoing clinical trials.",
author = "Kristina Khazeni and Hannah LaBove and Breelyn Wilky and Rosenberg, {Andrew E.} and Elizabeth Paulus and Harvey Chim and Pearson, {Joseph M.} and Danny Yakoub",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ijscr.2018.06.016",
language = "English (US)",
volume = "49",
pages = "239--243",
journal = "International Journal of Surgery Case Reports",
issn = "2210-2612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Myoepithelial carcinoma or epithelioid sarcoma – A rare diagnosis with poor prognosis. A case report and review of literature

AU - Khazeni, Kristina

AU - LaBove, Hannah

AU - Wilky, Breelyn

AU - Rosenberg, Andrew E.

AU - Paulus, Elizabeth

AU - Chim, Harvey

AU - Pearson, Joseph M.

AU - Yakoub, Danny

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Myoepithelial carcinoma and proximal-type epithelioid sarcoma of the vulva are two rare malignancies with known aggressive behavior. In addition to a similar clinical course, these two disease entities also have significant histologic and pathologic overlap. Given the rarity of these malignancies, there is limited literature on the appropriate treatment regimen. Nevertheless, there is a consensus that early surgical resection is beneficial in both cases. Presentation: We present a case of a patient who was initially diagnosed with myoepithelial carcinoma of the vulva with a differential later expanded to include possible epithelioid sarcoma. Discussion: We demonstrate the importance in early identification of a SMARCB1 deficiency. Additionally, we suggest an appropriate treatment regimen for these patients going forward. Specifically, we encourage consideration of bilateral superficial and deep inguinal lymphadenectomies. Furthermore, sarcoma based chemotherapy regimens in the appropriate clinical setting may be beneficial in treating SMARCB1 deficient tumors. Additionally, there are now clinical trials involving EZH2 Inhibitors which may offer benefit for similar patients going forward. Conclusion: This case highlights the difficulty in making a definitive diagnosis, and the importance in identifying a SMARCB1 deficiency as it will affect treatment options and may allow for enrollment in ongoing clinical trials.

AB - Introduction: Myoepithelial carcinoma and proximal-type epithelioid sarcoma of the vulva are two rare malignancies with known aggressive behavior. In addition to a similar clinical course, these two disease entities also have significant histologic and pathologic overlap. Given the rarity of these malignancies, there is limited literature on the appropriate treatment regimen. Nevertheless, there is a consensus that early surgical resection is beneficial in both cases. Presentation: We present a case of a patient who was initially diagnosed with myoepithelial carcinoma of the vulva with a differential later expanded to include possible epithelioid sarcoma. Discussion: We demonstrate the importance in early identification of a SMARCB1 deficiency. Additionally, we suggest an appropriate treatment regimen for these patients going forward. Specifically, we encourage consideration of bilateral superficial and deep inguinal lymphadenectomies. Furthermore, sarcoma based chemotherapy regimens in the appropriate clinical setting may be beneficial in treating SMARCB1 deficient tumors. Additionally, there are now clinical trials involving EZH2 Inhibitors which may offer benefit for similar patients going forward. Conclusion: This case highlights the difficulty in making a definitive diagnosis, and the importance in identifying a SMARCB1 deficiency as it will affect treatment options and may allow for enrollment in ongoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85050258099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050258099&partnerID=8YFLogxK

U2 - 10.1016/j.ijscr.2018.06.016

DO - 10.1016/j.ijscr.2018.06.016

M3 - Article

VL - 49

SP - 239

EP - 243

JO - International Journal of Surgery Case Reports

JF - International Journal of Surgery Case Reports

SN - 2210-2612

ER -